Scan to downloadKYORIN Pharmaceutical Co., Ltd. (4569) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-09 | Earnings Release | [Summary]Consolidated Financial Results for the Six Months Ended September 30, 2026 [Japanese GAAP] | |
| 2026-11-09 | Earnings Release | Consolidated Financial Results for Second Quarter of FY2026 - Supplementary Information | |
| 2026-11-09 | Forecast Revision | Notice Regarding Difference Between Financial Forecast and Actual Results and Revision | |
| 2026-11-09 | — | KYORIN and Edesa Biotech Enter into License Agreement for EB05 for ARDS (Acute Respiratory Distress Syndrome) | |
| 2026-10-28 | — | Notice Concerning Change in Major Shareholder | |
| 2026-09-30 | — | (Update on Disclosed Matter) Notice Regarding Transfer of Generic Drug Business | |
| 2026-08-03 | — | KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5% | |
| 2026-07-30 | Earnings Release | [Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP] | |
| 2026-07-30 | Earnings Release | Consolidated Financial Results for First Quarter of FY2026 - Supplementary Information | |
| 2026-07-13 | — | KYORIN Entered into Joint Marketing Agreement in Japan for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5% |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.